1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAI for Elder Care Research Program is sponsored by National Institute on Aging (NIA). This program supports research projects that develop and apply artificial intelligence technologies to improve health outcomes and quality of life for older adults, particularly those with Alzheimer's disease and related dementias.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
New Frontier in Aging Research | a2Collective. ai Updates The a2 Collective: A New Frontier in Aging Research Enlisting AI, new technology for an aging nation Despite average life expectancy doubling over the past two centuries, advancing age still brings with it increased risk of frailty and cognitive decline.
By 2060, an estimated 95 million Americans will be 65 or older and 17 percent of people age 75 to 84 are projected to develop Alzheimer’s disease or a related dementia. 1,2 The challenges of caring for large numbers of people with frailty and dementia are considerable, not only for individuals and their families, but for society at large.
In September 2021, the National Institute on Aging (NIA), part of the National Institutes of Health, launched the Artificial Intelligence and Technology Collaboratories (AITC) for Aging Research program.
3 Through the AITC program, NIA plans to award at least $40 million over a 5-year period to fund technology research, development, and demonstration projects likely to lead to practical commercial applications to promote healthy aging and improve care for people living with Alzheimer’s or a related dementia.
Three universities serve as major AITC hubs: Johns Hopkins University ( JH AITC ), the University of Massachusetts Amherst ( MassAITC ), and the University of Pennsylvania ( PennAITech ).
In addition to world-class research facilities and leadership from experts representing a range of scientific disciplines, each AITC brings a unique perspective to the program, with emphases on delivering engineered solutions to market, supporting healthy aging in the home, and integrating care and monitoring across home and clinical settings. Rose Li and Associates (RLA) serves as the Coordinating Center for the AITC program.
The three AITCs and the Coordinating Center together comprise the a2 Collective . Partha Bhattacharyya, PhD, NIA Division of Behavioral and Social Research program director and key architect of the AITC program, laid out the challenges and opportunities facing an aging population: “Development of technology for older adults lags behind and this likely contributes to disparities in health care.
The a2 Collective harnesses AI and technological innovation to enhance the health and well-being of older adults in a way that uniquely brings together people and resources to accelerate progress.
” The a2 Collective intentionally takes a collaborative approach to bring together experts and entrepreneurs with a wide range of experience—in medicine, geriatrics, clinical research, computer sciences, applied technologies, transportation, aging policy and public health, caregiving, stakeholder engagement, commercialization, and business development.
"The a2 Collective harnesses AI and technological innovation to enhance the health and well-being of older adults in a way that uniquely brings together people and resources to accelerate progress." The promise of transformational technology Previous advances in science, medicine, public health, and technology have played important roles in increasing life expectancy.
Now, next-generation technologies, including AI and machine learning, are being enlisted for their potential to further improve health and well-being. The public is already familiar with early AI applications such as web-based search engines, systems that understand human speech, and ride-sharing apps.
And newer technologies that might apply specifically to better health and care with age are already emerging, including personalized medical alert systems, active medication management, telehealth visits, sensors and wearable devices, GPS systems to track wandering individuals, health-related smartphone apps, and even assistance from robotic companions.
NIA envisions a broad array of AI applications providing help to older individuals and caregivers, including: • Ambient intelligence, which includes smart environments that can monitor for health risks • Affective computing, which recognizes and interprets human behaviors and emotions and can provide adaptive responses • Computer vision, which can assist in analyzing images and inform diagnostics • Natural language processing, which can help people affected by disorders of speech, hearing, language processing, and communication • Decision networks and probabilistic programming, which can support clinical decision making • Machine learning, which can help understand, predict, and respond to health risks such as injuries due to falls or monitor patients with progressive illnesses such as heart failure NIA will specifically direct funds to developing AI’s potential to assist individuals with dementia by helping to maintain cognitive faculties; address delirium and confusion; mitigate social isolation; and provide medication management, health monitoring, and much more.
"Recent trends in machine learning hold absolutely tremendous potential for digital medicine." In March 2023, the a2 Collective held its first national symposium at Johns Hopkins University. Rama Chellappa, PhD, co-principal investigator of JH AITC, captured the enthusiasm of the event: “Recent trends in machine learning hold absolutely tremendous potential for digital medicine—it’s a shame if we don’t take advantage of this!
” The in-person symposium , with speakers, posters, and encouraged interactions among attendees, showcased the first group of funded pilots —which includes projects aimed at the use of virtual reality to facilitate social engagement, AI-assisted chat device advisers to help caregivers, robotic assistants to detect and calm bouts of dementia-induced aggression in patients in residential centers, home-based movement sensors to predict cognitive decline, and wearable devices embedded in earbuds to monitor heart health.
Rose Li, PhD, MBA, principal investigator of the a2 Collective Coordinating Center, observed: “As the AITCs discover and identify the most promising technologies, investors can spur market testing—and ultimately, commercialization. ” A diverse group of dedicated scientists and tech innovators are stepping up to meet this challenge head on. Grant applications are now open to fund the next round of transformational projects.
NIA is one of 27 Institutes and Centers of the National Institutes of Health at the U.S. Department of Health and Human Services. The a2 Collective is funded through NIA grants U24AG073094 (the a2 Collective Coordinating Center), P30AG073104 (JH AITC), P30AG073105 (PennAITech), and P30AG073107 (MassAITC). 1.
Vespa, Jonathan, Lauren Medina, and David M. Armstrong, “Demographic Turning Points for the United States: Population Projections for 2020 to 2060,” Current Population Reports, P25-1144, U.S. Census Bureau, Washington, DC, 2020. https://www.
census. gov/content/dam/Census/library/publications/2020/demo/p25-1144. pdf 2.
(2020), 2020 Alzheimer's disease facts and figures. Alzheimer's Dement. , 16: 391-460.
https://doi. org/10. 1002/alz.
12068 3. The program’s formation began in September 2020, when NIA released a pair of funding opportunity announcements for AITCs ( RFA-AG-21-009 ) and an AITC Coordinating Center ( RFA-AG-21-018 ) that would together serve as a national resource promoting AI and technology development to enhance the health and well-being of older Americans, including persons with dementia and their caregivers.
Realizing the Emerging Potential at the Intersection of Artificial Intelligence and Dementia Current trends illustrate the rapid rise of applications of AI in dementia research and care—and underscore the vast potential that further... Apply for an RCCN Travel Award to Attend the Second Annual a2 National Symposium Early career investigator travel awards are available for the second annual a2 National Symposium in Philadelphia, PA, Mar.
19-20, 2024... Developing Innovative AI for Aging: From Idea to Real-World Impact On March 18, 2026, the a2 Collective hosted a series of pre-symposium workshops for recent a2 Pilot Awards–funded investigators...
According to the current listing, eligibility includes: Nonprofits, universities, state/local governments, and private institutions of higher education. Confirm the full requirements in the official notice before applying.
The current listing shows up to $500,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
AI for Elder Care Research Program is funded by National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article